| Theme |
Homocysteinemia in Association with Chronic Renal Failure |
| Title |
Hyperhomocysteinemia in chronically uremic patients |
| Author |
Tai Sakurabayashi |
Kidney Center of Shinraku-en Hospital |
| Author |
Yoshiji Takaesu |
Kidney Center of Shinraku-en Hospital |
| Author |
Susumu Haginosita |
Kidney Center of Shinraku-en Hospital |
| Author |
Shin Goto |
Kidney Center of Shinraku-en Hospital |
| Author |
Ikuo Aoike |
Kidney Center of Shinraku-en Hospital |
| Author |
Shigeru Miyazaki |
Kidney Center of Shinraku-en Hospital |
| Author |
Yutaka Koda |
Kidney Center of Shinraku-en Hospital |
| Author |
Yasuko Yuasa |
Kidney Center of Shinraku-en Hospital |
| Author |
Shinji Sasaki |
Kidney Center of Shinraku-en Hospital |
| Author |
Masasi Suzuki |
Kidney Center of Shinraku-en Hospital |
| Author |
Yoshihei Hirasawa |
Kidney Center of Shinraku-en Hospital |
| [ Summary ] |
The relationship of hyperhomocysteinemia to atherothrombosis has been shown experimentally and epidemiologically. The earlyprogression of atherosclerosis has been detected in chronic allyuremic patients and is a risk factor for the longevity of these patients. Because the majority of these patients have hyperhomocysteinemia, its pathogenesis and relationship to cardiovascular disease (CVD) has been studied. We examined plasma homocysteine by using the Araki and Sako method and examining the ratio in relation to cysteine in order to evaluate a part of the metabolic activity of homocysteine. In our results, we observed that almost all hemodialysis patients had hyperhomocysteinemia and the patients with CVD had significantly higher homocysteine concentrations than those without CVD. Furthermore, some of the patients with CVD had a high ratio of homocysteine to cysteine and seemed to have low metabolic activity for homocysteine. Our data support that hyperhomocysteinemia is a risk factor for CVD in chronically uremic patients. |